Examining the effects of serotonin on perceptual awareness and attention.
In healthy adults, how do buspirone and citalopram compared with placebo effect switch rate in perceptual rivalry?
The University of Melbourne
20 participants
Mar 1, 2011
Interventional
Conditions
Summary
Binocular rivalry occurs when different stimuli are presented to the left and right eye simultaneously. Under these conditions the observer will consciously perceive only one of the two images at a time, with the respective dominance of the two images alternating every few seconds. A similar phenomenon is also observed in hearing. Previous studies have shown that the rate of alternation is affected by certain medications that affect the serotonin system. We will administer two such medications to healthy individuals to further investigate how the serotonin system is involved in perceptual rivalry. The main implications of this study relate to pure research and understanding the neural mechanisms underlying perception. There is currently no clinical aim for this study.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Oral tablets of Buspirone (15mg), Citalopram (20mg) or placebo will be administered to healthy adults. Each participant will participate in 4 separate sessions of testing separated by at least 2 weeks: session1/Placebo + Buspirone (2.5 hours later), session2/ Citalopram + Buspirone (2.5 hours later), session3/ Placebo + Placebo (2.5 hours later), session4/ Citalopram + Placebo (2.5 hours later). The study will investigate the neurochemical basis of binocular rivalry, a phenomenon that is a feature of normal vision. No abnormal condition or disease is being investigated as part of this study. The medications in this study are already approved by the Australian Therapeutic Goods Administration.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12611000084987